Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) was the target of a large growth in short interest in December. As of December 15th, there was short interest totaling 42,256 shares, a growth of 142.6% from the November 30th total of 17,416 shares. Based on an average daily volume of 114,351 shares, the days-to-cover ratio is currently 0.4 days. Approximately 6.3% of the shares of the stock are sold short. Approximately 6.3% of the shares of the stock are sold short. Based on an average daily volume of 114,351 shares, the days-to-cover ratio is currently 0.4 days.

Analysts Set New Price Targets

A number of brokerages have issued reports on ACON. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Aclarion to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Aclarion Stock Down 8.3%

Shares of NASDAQ:ACON opened at $5.39 on Friday. Aclarion has a fifty-two week low of $5.02 and a fifty-two week high of $3,499.51. The firm’s 50 day moving average price is $6.68 and its 200 day moving average price is $7.24. The stock has a market cap of $3.61 million, a price-to-earnings ratio of -0.36 and a beta of 1.43.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.93) EPS for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Aclarion had a negative net margin of 10,908.50% and a negative return on equity of 67.53%. On average, equities analysts anticipate that Aclarion will post -263.33 EPS for the current year.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.